Impact of PD-L1 Expression on the Overall Survival of Patients
With Non-small Cell Lung Cancer Treated With Single-agent
Pembrolizumab

J 2024

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab

SVATON, Martin, Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK et. al.

Základní údaje

Originální název

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab

Autoři

SVATON, Martin (203 Česká republika), Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK (203 Česká republika, domácí), Jana KREJCI (203 Česká republika), Marie DROSSLEROVA (203 Česká republika), Michal HRNCIARIK (203 Česká republika), Daniel HRICISAK (203 Česká republika), Alzbeta BEJCKOVA (203 Česká republika), Ondrej FISCHER (203 Česká republika), Martina VITKOVA (203 Česká republika) a Maciej KRZAKOWSKI

Vydání

In vivo, Athens, International Institute of Anticancer Research, 2024, 0258-851X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.300 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/invivo.13712

UT WoS

001300248100042

Klíčová slova anglicky

Non-small cell lung cancer; pembrolizumab; overall survival; PD-L1 expression

Štítky

14110215, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 23. 9. 2024 13:16, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression >= 50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (>= 50%) >= 50%) in patients with NSCLC. Patients and Methods: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression >= 50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. Results: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD- L1 in the Cox regression model including the effect covariates. Conclusion: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD- L1 >= 50% >= 50% treated with pembrolizumab.

Citovat

SVATON, Martin, Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK, Jana KREJCI, Marie DROSSLEROVA, Michal HRNCIARIK, Daniel HRICISAK, Alzbeta BEJCKOVA, Ondrej FISCHER, Martina VITKOVA a Maciej KRZAKOWSKI. Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab. In vivo. Athens: International Institute of Anticancer Research, 2024, roč. 38, č. 5, s. 2434-2440. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.13712.

@article{2436079,
   author = {Svaton, Martin and KnetkiandWroblewska, Magdalena and Tabor, Sylwia and Domecky, Petr and Venclíček, Ondřej and Krejci, Jana and Drosslerova, Marie and Hrnciarik, Michal and Hricisak, Daniel and Bejckova, Alzbeta and Fischer, Ondrej and Vitkova, Martina and Krzakowski, Maciej},
   article_location = {Athens},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/invivo.13712},
   keywords = {Non-small cell lung cancer; pembrolizumab; overall survival; PD-L1 expression},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab},
   url = {https://iv.iiarjournals.org/content/38/5/2434},
   volume = {38},
   year = {2024}
}

TY  - JOUR
ID  - 2436079
AU  - Svaton, Martin - Knetki-Wroblewska, Magdalena - Tabor, Sylwia - Domecky, Petr - Venclíček, Ondřej - Krejci, Jana - Drosslerova, Marie - Hrnciarik, Michal - Hricisak, Daniel - Bejckova, Alzbeta - Fischer, Ondrej - Vitkova, Martina - Krzakowski, Maciej
PY  - 2024
TI  - Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
JF  - In vivo
VL  - 38
IS  - 5
SP  - 2434-2440
EP  - 2434-2440
PB  - International Institute of Anticancer Research
SN  - 0258851X
KW  - Non-small cell lung cancer
KW  - pembrolizumab
KW  - overall survival
KW  - PD-L1 expression
UR  - https://iv.iiarjournals.org/content/38/5/2434
N2  - Background/Aim: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression >= 50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (>= 50%) >= 50%) in patients with NSCLC. Patients and Methods: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression >= 50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. Results: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD- L1 in the Cox regression model including the effect covariates. Conclusion: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD- L1 >= 50% >= 50% treated with pembrolizumab.
ER  -

SVATON, Martin, Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK, Jana KREJCI, Marie DROSSLEROVA, Michal HRNCIARIK, Daniel HRICISAK, Alzbeta BEJCKOVA, Ondrej FISCHER, Martina VITKOVA a Maciej KRZAKOWSKI. Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab. \textit{In vivo}. Athens: International Institute of Anticancer Research, 2024, roč.~38, č.~5, s.~2434-2440. ISSN~0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.13712.

Podrobný výpis o publikaci